Goldline Pharmaceutical Limited (BOM:544759)
India · Delayed Price · Currency is INR 38.84
-1.55 (-3.84%)
At close: Jul 14, 2026
Goldline Pharmaceutical Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 311.98 | 280.56 | 235.66 | 198.48 | 240.11 |
Other Revenue | 0.01 | - | - | - | - |
| 311.99 | 280.56 | 235.66 | 198.48 | 240.11 | |
Revenue Growth (YoY) | 11.20% | 19.05% | 18.73% | -17.34% | 9.66% |
Cost of Revenue | 111.9 | 108.39 | 60.86 | 58.5 | 154.02 |
Gross Profit | 200.09 | 172.16 | 174.8 | 139.99 | 86.08 |
Selling, General & Admin | 70.7 | 58.37 | 58.04 | 56.33 | 54.41 |
Other Operating Expenses | 59.97 | 52.32 | 73.3 | 59.52 | 14.63 |
Operating Expenses | 133.09 | 113.2 | 132.98 | 117.6 | 69.54 |
Operating Income | 67 | 58.97 | 41.82 | 22.39 | 16.54 |
Interest Expense | -13.15 | -18.48 | -14.78 | -15.35 | -12.11 |
Interest & Investment Income | - | - | - | - | 0.07 |
Other Non Operating Income (Expenses) | - | -0.99 | -1.35 | -0.98 | - |
EBT Excluding Unusual Items | 53.85 | 39.5 | 25.69 | 6.05 | 4.5 |
Gain (Loss) on Sale of Assets | - | -0.91 | -0.42 | -2.04 | - |
Pretax Income | 53.85 | 38.58 | 25.27 | 4.01 | 4.5 |
Income Tax Expense | 12.68 | 10.24 | 7.21 | 1.45 | 1.19 |
Net Income | 41.17 | 28.34 | 18.06 | 2.57 | 3.32 |
Net Income to Common | 41.17 | 28.34 | 18.06 | 2.57 | 3.32 |
Net Income Growth | 45.27% | 56.93% | 603.82% | -22.64% | 60.38% |
Shares Outstanding (Basic) | 7 | 7 | 6 | 6 | 6 |
Shares Outstanding (Diluted) | 7 | 7 | 6 | 6 | 6 |
Shares Change (YoY) | -0.05% | 14.95% | 0.04% | 0.09% | -0.49% |
EPS (Basic) | 5.97 | 4.11 | 3.01 | 0.43 | 0.55 |
EPS (Diluted) | 5.97 | 4.11 | 3.01 | 0.43 | 0.55 |
EPS Growth | 45.34% | 36.52% | 603.53% | -22.71% | 61.17% |
Free Cash Flow | 27.58 | 21.14 | 18.14 | 12.83 | - |
Free Cash Flow Per Share | 4.00 | 3.06 | 3.02 | 2.14 | - |
Gross Margin | 64.13% | 61.37% | 74.17% | 70.53% | 35.85% |
Operating Margin | 21.48% | 21.02% | 17.75% | 11.28% | 6.89% |
Profit Margin | 13.20% | 10.10% | 7.66% | 1.29% | 1.38% |
Free Cash Flow Margin | 8.84% | 7.54% | 7.70% | 6.46% | - |
EBITDA | 69.41 | 61.47 | 43.46 | 24.14 | 17.05 |
EBITDA Margin | 22.25% | 21.91% | 18.44% | 12.16% | 7.10% |
D&A For EBITDA | 2.41 | 2.5 | 1.64 | 1.75 | 0.51 |
EBIT | 67 | 58.97 | 41.82 | 22.39 | 16.54 |
EBIT Margin | 21.48% | 21.02% | 17.75% | 11.28% | 6.89% |
Effective Tax Rate | 23.55% | 26.54% | 28.53% | 36.06% | 26.34% |
Revenue as Reported | 311.99 | 280.56 | 235.66 | 198.49 | 240.18 |
Advertising Expenses | - | 0.3 | 1.71 | 1.59 | 0.6 |